Active	Status	Sponsor type	Region	Phase	Filter
1 Active 3 Inactive 4 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

1 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Ulm, Michael A
GLORIOSA, NCT05445778: Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Ovarian, Fallopian Tube, or Peritoneal Cancer	Recruiting	3	418	Europe, Canada, US, RoW	Mirvetuximab soravtansine plus Bevacizumab, MIRV, Bevacizumab	ImmunoGen, Inc., GOG Foundation	Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer	03/27	04/29
Bowden, Michelle
No trials found